familial hypercholesterolaemia
Cardiovascular · 2016–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| evolocumab Treatment of homozygous familial hypercholesterolaemia (HoFH), heterozygous familial hypercholesterolaemia (HeFH) and non-familial hypercholesterolaemia… | Mar 2024 | Recommended with restriction | 1 individuals |
| inclisiran Amendment to restriction level (Authority Required Telephone/Online to Authority Required STREAMLINED) for initial and grandfathered listings for treatment of… | Nov 2024 | Recommended with restriction | input received Heart Support Australia |
| evolocumab Treatment of homozygous familial hypercholesterolaemia (ho-FH), heterozygous familial hypercholesterolaemia (he-FH), and non-FH hypercholesterolaemia in… | Mar 2021 | Recommended | none received |
| evolocumab Amendment to treatment criteria for evolocumab for familial hypercholesterolaemia (homozygous and heterozygous) and non-familial hypercholesterolaemia to allow… | Nov 2020 | Not recommended | input received |
| evolocumab Treatment of patients with Familial Hypercholesterolaemia (FH) and either symptomatic atherosclerotic cardiovascular disease (ASCVD) or FH with very high… | Mar 2018 | Recommended with restriction | none received |
| evolocumab Treatment of familial hypercholesterolaemia (homozygous familial hypercholesterolaemia recommended; heterozygous familial hypercholesterolaemia not… | Mar 2016 | Recommended with restriction | input received Familial Hypercholesterolaemia Australasia Network · FH Family Support Group |
Who spoke
Familial Hypercholesterolaemia Australasia Network · FH Family Support Group · Heart Support Australia
What the PBS pays
$101M in government benefit over 2024–25, across 197,739 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| evolocumab | $63.2M |
| inclisiran | $38.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.